588 related articles for article (PubMed ID: 19907154)
1. Deferasirox (Exjade) for the treatment of iron overload.
Cappellini MD; Taher A
Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Imran F; Phatak P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
[TBL] [Abstract][Full Text] [Related]
3. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox: pharmacokinetics and clinical experience.
Galanello R; Campus S; Origa R
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
[TBL] [Abstract][Full Text] [Related]
5. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
Cancado R; Olivato MC; Bruniera P; Szarf G; de Moraes Bastos R; Rezende Melo M; Chiattone C
Acta Haematol; 2012; 128(2):113-8. PubMed ID: 22760067
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of deferasirox.
Cappellini MD
Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
[TBL] [Abstract][Full Text] [Related]
8. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
Wimazal F; Nösslinger T; Baumgartner C; Sperr WR; Pfeilstöcker M; Valent P
Eur J Clin Invest; 2009 May; 39(5):406-11. PubMed ID: 19320908
[TBL] [Abstract][Full Text] [Related]
9. Deferasirox for transfusion-related iron overload: a clinical review.
Lindsey WT; Olin BR
Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
[TBL] [Abstract][Full Text] [Related]
10. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox--an oral agent for chronic iron overload.
Vanorden HE; Hagemann TM
Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
[TBL] [Abstract][Full Text] [Related]
12. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
Yang LP; Keam SJ; Keating GM
Drugs; 2007; 67(15):2211-30. PubMed ID: 17927285
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
Taher AT; Temraz S; Cappellini MD
Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
Shirley M; Plosker GL
Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
17. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
18. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
Voskaridou E; Plata E; Douskou M; Sioni A; Mpoutou E; Christoulas D; Dimopoulou M; Terpos E
Ann Hematol; 2011 Jan; 90(1):11-5. PubMed ID: 20661572
[TBL] [Abstract][Full Text] [Related]
20. Chelation therapy for iron overload.
Barton JC
Curr Gastroenterol Rep; 2007 Mar; 9(1):74-82. PubMed ID: 17335681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
